Travere Therapeutics Inc(TVTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.76 | Insider Own | 2.96% | Shs Outstand | 94.2M | Perf Week | 0.62% |
| Market Cap | 4.75B | Forward P/E | 17.61 | EPS next Y | 1318.39% | Insider Trans | -33.75% | Shs Float | 91.5M | Perf Month | -11.36% |
| Enterprise Value | 4.88B | PEG | - | EPS next Q | -0.1 | Inst Own | 114.41% | Short Float | 11.93% | Perf Quarter | -8.35% |
| Income | -0.07B | P/S | 8.03 | EPS this Y | 19.03% | Inst Trans | 4.92% | Short Ratio | 6.17 | Perf Half Y | 14.21% |
| Sales | 0.59B | P/B | 193.52 | EPS next 5Y | - | ROA | -9.99% | Short Interest | 10.91M | Perf YTD | 31.88% |
| Book/sh | 0.26 | P/C | 9.71 | EPS past 3/5Y | 49.47% 30.85% | ROE | -236.35% | 52W High | -26.68% ($68.73) | Perf Year | 69.95% |
| Cash/sh | 5.19 | P/FCF | 51.11 | Sales past 3/5Y | 64.89% 19.87% | ROIC | -10.65% | 52W Low | 123.06% ($22.59) | Perf 3Y | 645.41% |
| Dividend Est. | - | EV/EBITDA | 212.9 | EPS Y/Y TTM | 64.4% | Gross Margin | 87.89% | Volatility(W/M) | 4.19% 4.28% | Perf 5Y | 74.9% |
| Dividend TTM | - | EV/Sales | 8.25 | Sales Y/Y TTM | 77.12% | Oper. Margin | -6.84% | ATR (14) | 2.28 | Perf 10Y | 165.07% |
| Dividend Ex-Date | - | Quick Ratio | 3.99 | EPS Q/Q | -159.55% | Profit Margin | -11.45% | RSI (14) | 35.44 | Recom | 1.13 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.05 | Sales Q/Q | 48.17% | SMA20 | -3.21% ($52.06) | Beta | 1.1 | Target Price | $75.21 |
| Payout | - | Debt/Eq | 25.16 | Earnings | 2026/11/2 | SMA50 | -14.68% ($59.06) | Rel Volume | 0.64 | Prev Close | $50.57 |
| Employees | 497 | LT Debt/Eq | 24.91 | EPS/Sales Surpr. | -174.68% 7.83% | SMA200 | 8.09% ($46.62) | Avg Volume(3M) | 1.77M | Price | $50.39 |
| IPO | 2003/10/6 | Option/Short | Yes/Yes | Trades | 12146 | Volume | 1,139,432 | Change | -0.36% |
🧬 This is a biopharmaceutical company that develops and sells treatments for rare kidney diseases. Its flagship product, Filspari (sparsentan), has been launched for immunoglobulin A nephropathy as its indication, and the company is working to expand indications to include conditions such as focal segmental glomerulosclerosis. It is a commercial-stage biopharmaceutical company specializing in rare kidney diseases.
Over the past 1 year, roughly in the middle
27% below its 1-year high.
Traded less than usual. That is 64% of its average volume.
Next earnings report: November 2
2 days to go.
TVTX has weak earning power
Of every $100 in sales, $6.84 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +19.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $803. Peers typically go for $1,560.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +74.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 114.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #54 of 597 in the industry
Based on market cap of $5B.
PTCT#51 PTC Therapeutics Inc $5B PER - 
CRSP#52 CRISPR Therapeutics AG $5B PER - 
DFTX#53 Definium Therapeutics Inc $5B PER - TVTX#54 Travere Therapeutics Inc $5B PER - 
DNTH#55 Dianthus Therapeutics Inc $5B PER - 
FAQ
What kind of company is TVTX?
TVTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TVTX?
The market cap of TVTX is approximately $4.7B, ranking 1,407 within its sector.
What is the 52-week high and low for TVTX?
TVTX has recorded a 52-week high of $68.73 and a low of $22.59.
